Alnylam Pharmaceuticalsvs.BioMarin Pharmaceutical
ALNY vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 3.5× larger than BioMarin Pharmaceutical by market cap; BioMarin Pharmaceutical trades at the lower P/E (42.6 vs 69.1); year to date, BioMarin Pharmaceutical leads (−0.5% vs −24.9%).
Side by side
| ALNY | BMRN | |
|---|---|---|
| Market cap | $39.9B | $11.4B |
| Price | $298.76 | $59.12 |
| Today | −4.5% | −1.4% |
| Return YTD | −24.9% | −0.5% |
| Return 1Y | −7.4% | +0.5% |
| P/E | 69.1 | 42.6 |
| P/S | 9.3 | 3.5 |
| P/B | 37.1 | 1.8 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →BioMarin PharmaceuticalBMRN
Biopharma specialized in enzyme and gene therapies for rare genetic diseases.
Full BMRN profile →More comparisons in Biotech & innovation
See where ALNY and BMRN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →